Joint Development of Biosimilars in the Field of Cancer Treatment
First written in FY2016. 8 of 11 entries say "Restated". Latest entry: FY2020.
0 other companies' latest entry also says "Restated".
- FY2020RestatedAnnual report
「In December 2016, we entered into a joint commercialization agreement with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field and began development. Going forward, we will work diligently toward launching this development product through mutual cooperation.」
Development and efforts toward the launch of the oncology biosimilar with Mochida Pharmaceutical Co.,Ltd. continue under the joint commercialization agreement. - FY2019RestatedAnnual report
「In December 2016, we entered into a joint commercialization agreement with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field and began development. Going forward, we will work diligently toward launching this development product through mutual cooperation.」
Development and efforts toward the launch of the oncology biosimilar with Mochida Pharmaceutical Co.,Ltd. continue under the joint commercialization agreement. - FY2019-Q1RestatedAnnual report
「③ Business partnership with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field」
The partnership with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field and joint development aimed at obtaining approval continue. - FY2018RestatedAnnual report
「In August 2015, we entered into a basic agreement with Mochida Pharmaceutical Co.,Ltd. for the joint development of a biosimilar in the oncology field, and in December 2016, entered into a joint commercialization agreement to ensure the successful launch of the biosimilar. We have continued to steadily advance development since then.」
Development of the oncology biosimilar with Mochida Pharmaceutical Co.,Ltd. continues under the joint commercialization agreement. - FY2018-Q3RestatedAnnual report
「In December of the same year, we entered into a joint commercialization agreement with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field and began joint development aimed at obtaining marketing approval.」
The joint commercialization agreement and joint development with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field continue. - FY2018-Q2RestatedAnnual report
「③ Business partnership with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field」
The partnership with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field continues to be listed as a development program. - FY2017Cited as achievedAnnual report
「In August 2015, we entered into a basic agreement with Mochida Pharmaceutical Co.,Ltd. for the joint development of a biosimilar in the oncology field, and in December 2016, entered into a joint commercialization agreement to ensure the successful launch of the biosimilar.」
The joint commercialization agreement with Mochida Pharmaceutical Co.,Ltd. for the oncology biosimilar is being described as an achieved milestone. - FY2017-Q3AdvancedAnnual report
「In addition, in December of the same year, we entered into a joint commercialization agreement with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field and began joint development aimed at obtaining marketing approval, marking steady progress.」
The initiative progressed from the previous business partnership to the execution of a joint commercialization agreement with Mochida Pharmaceutical Co.,Ltd. and the start of joint development aimed at obtaining marketing approval. - FY2017-Q2RestatedAnnual report
「③ Business partnership with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field」
The partnership with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field continues to be pursued as part of our development and business initiatives. - FY2017-Q1RestatedAnnual report
「③ Business partnership with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field」
The partnership with Mochida Pharmaceutical Co.,Ltd. for a biosimilar in the oncology field continues to be promoted. - FY2016First statedAnnual report
「Since August 2015, we have been jointly developing a biosimilar in the oncology field with Mochida Pharmaceutical Co.,Ltd. and are working diligently toward launching a biosimilar in this therapeutic area.」
A biosimilar in the oncology field is being developed through the partnership with Mochida Pharmaceutical Co.,Ltd.